2022
Benzodiazepines and Related Sedatives
Peng L, Morford KL, Levander XA. Benzodiazepines and Related Sedatives. Medical Clinics Of North America 2022, 106: 113-129. PMID: 34823725, DOI: 10.1016/j.mcna.2021.08.012.ChaptersConceptsLong-term benzodiazepine useQuality of evidenceRisk of overdoseSignificant adverse effectsCognitive behavioral therapySedative useBenzodiazepine useBenzodiazepine discontinuationPharmacologic propertiesBenzodiazepine taperWithdrawal managementPhysical dependenceBehavioral treatmentBehavioral therapyBenzodiazepinesDetoxification facilityNovel psychoactive substancesAdverse effectsDesigner benzodiazepinesPsychoactive substancesMost benefitDiscontinuationMedicationsSedativesOverdose
2021
Readiness to Provide Medications for Addiction Treatment in HIV Clinics: A Multisite Mixed-Methods Formative Evaluation
Edelman EJ, Gan G, Dziura J, Esserman D, Morford KL, Porter E, Chan PA, Cornman DH, Oldfield BJ, Yager JE, Muvvala SB, Fiellin DA. Readiness to Provide Medications for Addiction Treatment in HIV Clinics: A Multisite Mixed-Methods Formative Evaluation. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2021, 87: 959-970. PMID: 33675619, PMCID: PMC8192340, DOI: 10.1097/qai.0000000000002666.Peer-Reviewed Original ResearchConceptsHIV clinicTreatment medicationsMixed-methods formative evaluationAddiction treatmentTreatment-eligible patientsSubscale scoresAddiction treatment medicationsAdverse health consequencesHIV careMedication complexityTobacco useMedicationsClinicHealth consequencesSite specialistMultidisciplinary teamworkBehavioral servicesTreatment modelOpioidsLocal championsVariable experienceInconsistent availabilityAddiction treatment modelsFocus groupsTreatment
2020
Working with HIV clinics to adopt addiction treatment using implementation facilitation (WHAT-IF?): Rationale and design for a hybrid type 3 effectiveness-implementation study
Edelman EJ, Dziura J, Esserman D, Porter E, Becker WC, Chan PA, Cornman DH, Rebick G, Yager J, Morford K, Muvvala SB, Fiellin DA. Working with HIV clinics to adopt addiction treatment using implementation facilitation (WHAT-IF?): Rationale and design for a hybrid type 3 effectiveness-implementation study. Contemporary Clinical Trials 2020, 98: 106156. PMID: 32976995, PMCID: PMC7511156, DOI: 10.1016/j.cct.2020.106156.Peer-Reviewed Original ResearchConceptsHIV clinicImplementation facilitationAddiction treatmentHealth services research frameworkHybrid type 3Effectiveness-implementation studyEvidence-based counselingSubstantial morbidityClinical outcomesOpioid misusePromoting ActionEffectiveness outcomesClinicFacilitators of integrationType 3Implementation outcomesTreatmentOutcomesWedge designHIVResearch implementationStudy goalFacilitation studiesStaff readinessMedications
2019
Pain symptomology, functional impact, and treatment of people with Neurofibromatosis type 1
Buono FD, Grau LE, Sprong ME, Morford KL, Johnson KJ, Gutmann DH. Pain symptomology, functional impact, and treatment of people with Neurofibromatosis type 1. Journal Of Pain Research 2019, 12: 2555-2561. PMID: 31692483, PMCID: PMC6710538, DOI: 10.2147/jpr.s209540.Peer-Reviewed Original ResearchNeurofibromatosis type 1Pain severityPain symptomsType 1Potential adverse side effectsPrescription pain medicationAdverse side effectsTreatment of peopleMedication dependenceOpioid medicationsPain medicationPain managementPain symptomatologyCurrent treatmentMalignant tumorsPain dataSurgical proceduresComplementary treatmentHigh incidenceAlternative treatmentSide effectsCareful monitoringMedicationsDaily functioningInitiative databaseMethadone Matters: What the United States Can Learn from the Global Effort to Treat Opioid Addiction
Calcaterra SL, Bach P, Chadi A, Chadi N, Kimmel SD, Morford KL, Roy P, Samet JH. Methadone Matters: What the United States Can Learn from the Global Effort to Treat Opioid Addiction. Journal Of General Internal Medicine 2019, 34: 1039-1042. PMID: 30729416, PMCID: PMC6544670, DOI: 10.1007/s11606-018-4801-3.Commentaries, Editorials and LettersConceptsOpioid use disorderLife-saving medicationsUse disordersOpioid use disorder treatmentIllicit opioid useUse of medicationsPharmacy-based modelsUse disorder treatmentOpioid useMethadone therapyOpioid epidemicOpioid overdoseOpioid addictionMedicationsMethadoneDisorder treatmentDisordersLogistical barriersTreatmentMajority of peopleMortalityMorbidityBuprenorphineLack accessOverdose